# Corvus Pharmaceuticals Inc. (CRVS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.39, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Corvus Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.7%** (5-yr avg -34.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -25.0%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 48.0%**. Earnings per share rose 48.0%.

## Financial health
- **Current ratio: 6.21** (quick 6.21). Current assets cover the next year's liabilities 6.21 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Corvus Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 151.1%** (YTD 86.9%, 3-mo 29.4%). The shares are up 151.1% over twelve months including dividends.
- **From 52-week high: -46.6%** (155.1% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): -0.42** (volatility 179%). Beta of -0.42 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRVS · Page: https://foliofundamentals.com/stocks/crvs

Not investment advice.